NEW YORK, June 25 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today that the Company has entered into definitive agreements with certain accredited investors (the "Investors") to sell in a registered direct offering 2,325,582 units with an aggregate gross offering price of $5 million. Each unit was priced at $2.15 and consists of one share of common stock and a warrant which will allow the Investor, for a period of two years, to purchase .25 share of common stock at a per share price of $2.75. The warrants may be called by the Company in the event that the common stock trades over $4.50 for 10 consecutive trading days. If fully exercised the warrants would result in additional gross proceeds to the Company of $1,598,837.
On the conclusion of the direct offering, Dr. Robin Smith, Chairman and
CEO noted, "We were pleased by the participation of new institutional
investors. We remain committed to expanding our revenue opportunities in China,
both through our pharmaceutical business and recently launched adult stem cell
initiatives." The Company intends to use the net proceeds from this offering
for the construction of lab facilities in China, stem cell-related research
and development projects, development and licensing of new pharmaceutical
products in China, and for working
|SOURCE NeoStem, Inc.|
Copyright©2010 PR Newswire.
All rights reserved